1. Home
  2. RDCM vs RCEL Comparison

RDCM vs RCEL Comparison

Compare RDCM & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Radcom Ltd.

RDCM

Radcom Ltd.

HOLD

Current Price

$16.07

Market Cap

205.1M

Sector

Technology

ML Signal

HOLD

Logo Avita Medical Inc.

RCEL

Avita Medical Inc.

HOLD

Current Price

$4.40

Market Cap

171.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RDCM
RCEL
Founded
1985
N/A
Country
Israel
United States
Employees
N/A
226
Industry
Computer peripheral equipment
Medical/Dental Instruments
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
205.1M
171.5M
IPO Year
1999
N/A

Fundamental Metrics

Financial Performance
Metric
RDCM
RCEL
Price
$16.07
$4.40
Analyst Decision
Strong Buy
Buy
Analyst Count
1
5
Target Price
$18.00
$7.88
AVG Volume (30 Days)
177.4K
211.8K
Earning Date
05-13-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$11.50
$17.17
Revenue Next Year
$9.74
$49.82
P/E Ratio
$16.35
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.41
$3.22
52 Week High
$16.49
$9.85

Technical Indicators

Market Signals
Indicator
RDCM
RCEL
Relative Strength Index (RSI) 77.55 49.09
Support Level $12.26 $4.37
Resistance Level $16.49 $4.57
Average True Range (ATR) 0.74 0.37
MACD 0.27 -0.06
Stochastic Oscillator 91.33 19.25

Price Performance

Historical Comparison
RDCM
RCEL

About RDCM Radcom Ltd.

Radcom Ltd Ltd is engaged in providing network intelligence, 5G ready cloud-native, network intelligence solutions for telecom operators transitioning to 5G. The company has a network intelligence solution for 5G namely Radcom ACE. Its products consist of Radcom Network Visibility, Radcom Service Assurance, and Radcom Network Insights. It has offices in Israel, the United States, Brazil, and India. Key revenue is derived from sales in North America.

About RCEL Avita Medical Inc.

Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.

Share on Social Networks: